STA-9584
STA-9584 is a potent vascular disrupting agent (VDA) that targets tubulin. STA-9584 exhibits potent antitumor activity in mouse xenograft model by selectively targeting microvasculature at both the center and periphery of tumors. STA-9584 can be used for research in prostate and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 906481-23-0
- Formule: C28H30ClN3O6
- Masse moléculaire:540.01
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice (7-12 weeks old) subcutaneously implanted with EMT6 cells[1]
-
Dosage:4.5 mg/kg
-
Administration:i.v., weekly for 2 weeks
-
Result:Completely blocked blood flow in highly perfused tumor subregions within 4 h of drug administration.
Completely arrested tumor growth over this period with a single dose for 24 h.
Exhibited far more extensive cellular destruction throughout the entire tumor, including areas of fibrosis and dramatically reduced viable rim or surviving tumor zones.
Resulted in no detectable viable rim tissue in many tumor sections.
Increased microvasculature destruction and consequent apoptosis in peripheral regions of tumors.
Induced widespread disruption of tumor microvessels, characterized by decreased, patchy CD31 expression, loss of integrity, and thrombosis.
Decreased CD31 endothelial cells in the viable rim by 77%.
-
Animal Model:Female BALB/c nude mice (7-12 weeks old) subcutaneously implanted with PC-3 cells[1]
-
Dosage:4.5 mg/kg
-
Administration:i.v., weekly for 3 weeks
-
Result:Induced significantly tumor regression (40%) compared with the control group.
Was well tolerated with minimal loss of body weight during the course of treatment.
-
Animal Model:Female CB-17/ Icr-Prkdcscid (SCID) mice (7-12 weeks old) subcutaneously implanted with MDA-MB-231 cells[1]
-
Dosage:4.5 mg/kg
-
Administration:i.v., weekly for 3 weeks
-
Result:Resulted in 60% tumor regression.
Chemical Information
-
CAS No. 906481-23-0
-
Masse moléculaire 540.01
-
Formule C28H30ClN3O6
-
SMILES
O=C(NC1=CC(C2=C(C3=CC(OC)=C(OC)C(OC)=C3)ON=C2)=CC=C1OC)[C@@H](N)CC4=CC=CC=C4.Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
STA-9584 Related Classifications
HY-111170 Related Classifications
Powered by Bioz